| First Author | Lattanzio G | Year | 1997 |
| Journal | Am J Pathol | Volume | 151 |
| Issue | 3 | Pages | 689-96 |
| PubMed ID | 9284817 | Mgi Jnum | J:42869 |
| Mgi Id | MGI:1096689 | Citation | Lattanzio G, et al. (1997) Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice [see comments]. Am J Pathol 151(3):689-96 |
| abstractText | Interleukin (IL)-6 is known to be an essential growth factor for myeloma cells, both in vitro and in vivo. In mice, IL-6 is required for development of B cell tumors upon infection with a retrovirus expressing the myc/raf oncogenes. In the present study, we used the pristane-oil-induced plasmacytoma model, which more closely mimics tumor transformation and progression in human multiple myeloma. Also using this system, we found that IL-6-deficient BALB/c mice are protected against tumor development. Although the pristane-induced inflammatory reaction was less pronounced in IL-6-deficient mice versus their wild-type littermates, both B cell differentiation and plasma cell formation took place, and even morphological evidence of plasma cell transformation was detected, albeit at a low frequency. However, in the absence of IL-6, there were never signs of uncontrolled proliferation of either normal B lymphocytes or tumor cells, suggesting that the role of IL-6 in murine plasmacytoma and possibly also in human multiple myeloma is to ensure abnormal survival and proliferation of previously transformed tumor cells and therefore tumor development and progression. |
